These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39410032)

  • 1. TSH Stimulation before PET/CT as Our Frenemy in Detecting Thyroid Cancer Metastases-Final Results of a Retrospective Analysis.
    Kołodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Durma AD; Niemczyk S; Kamiński G
    Cancers (Basel); 2024 Oct; 16(19):. PubMed ID: 39410032
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
    Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
    Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer.
    Rendl G; Rettenbacher L; Schweighofer-Zwink G; Hehenwarter L; Pirich C
    Horm Metab Res; 2020 Mar; 52(3):158-167. PubMed ID: 32215887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
    Petrich T; Börner AR; Otto D; Hofmann M; Knapp WH
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):641-7. PubMed ID: 11976802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer.
    Ledwon A; Paliczka-Cieślik E; Syguła A; Olczyk T; Kropińska A; Kotecka-Blicharz A; Hasse-Lazar K; Kluczewska-Gałka A; Jarząb B; Handkiewicz-Junak D
    Ann Nucl Med; 2021 Nov; 35(11):1214-1222. PubMed ID: 34363597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
    Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
    PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
    Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Performance of [
    Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
    J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
    Leboulleux S; Schroeder PR; Busaidy NL; Auperin A; Corone C; Jacene HA; Ewertz ME; Bournaud C; Wahl RL; Sherman SI; Ladenson PW; Schlumberger M
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Pituitary Fluorine-18-Fluorodeoxyglucose Uptake in Patients with Differentiated Thyroid Cancer in Hypothyroidism versus under Recombinant Human Thyroid-Stimulating Hormone Stimulation.
    Shi X; Giordani I; Nicod Lalonde M; Sykiotis GP
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Diagnostic Value of
    Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
    Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
    [No Abstract]   [Full Text] [Related]  

  • 20. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.